Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals LibraryNHS NIHR - National
Children exposed to progestogens in utero: excess cancers? Prescrire IN ENGLISH - Spotlight ''Children exposed to progestogens in utero: excess cancers?'', 1 March 2025 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards * Advancing : register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Children exposed to progestogens in utero: excess cancers? SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90 Spotlight * 100 most recent * Archives Children exposed to progestogens in utero
Treatments of unscheduled vaginal bleeding due to progestin-only contraception. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness, safety, and side effects associated with the usage of different treatments for unscheduled vaginal bleeding in premenopausal women using progestin-only pills.
FSRH CEU Statement: Drospirenone Progestogen-only Pill 1 FSRH CEU statement: Drospirenone 4mg progestogen-only Pill (Slynd®) 10 Jan 2024 A new drospirenone progestogen-only pill (DRSP POP) Slynd® is now available in the UK.1 CEU recommendations and guidance about DRSP POP can be found in the FSRH Progestogen Only Pills Guideline (2022)2. The following is a brief summary of key information. Pill guidance on missed pill management and requirement for emergency contraception when DRSP POP is used incorrectly can be found in the ‘Progestogen Only Pills’ Guideline FSRH Progestogen Only Pills Guideline .2 Contraceptive effectiveness Like the desogestrel POP, the DRSP POP acts primarily to suppress ovulation, with additional contraceptive effects on cervical mucus and endometrium.3 Studies3-5 indicate
FSRH CEU Statement: Response to new study by Roland et al Use of progestogens and the risk of intracranial meningioma FSRH CEU Statement: Response to new study by Roland et al (2024). Use of progestogens and the risk of intracranial meningioma: national case-control study. 28th March 2024 Background Meningioma is an uncommon and predominantly benign tumour. Incidence increases significantly with age, the median age at diagnosis being 66 years old. The incidence in patients over 40 is 18.69/100,000 and in patients aged 0-19 is 0.16/100,000. The main risk factors are advanced age and being female. (1) New evidence A paper published in the BMJ on the 27th March 2024 looked at the use of progestogens and the risk of intracranial meningioma requiring surgery. This national case-control study
Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers
FSRH Clinical Guideline: Progestogen-only Injectables FACULTY OF SEXUAL & REPRODUCTIVE HEALTHCARE Faculty of Sexual & Reproductive Healthcare Clinical Guidance Progestogen-only Injectable Contraception Clinical Effectiveness Unit December 2014 (Amended July 2023) DETAILS OF CHANGES TO ORIGINAL GUIDANCE DOCUMENT Since this set of guidelines was first published, the following changes have been the endorsement of respected authorities Good Practice Point where no evidence exists but where best practice is based on the clinical experience of the guideline group Document reference number 02/FSRH/Injectable/2014 Title Progestogen-only Injectable Contraception Author/publisher Faculty of Sexual & Reproductive Healthcare (FSRH) Publication date December 2014 (Amended July 2023) Description/descriptors
Contraception - progestogen-only methods CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If you
Giving the progestogen only pill along with emergency contraception encouraged women to use long-term contraception NIHR Evidence - Giving the progestogen only pill along with emergency contraception encouraged women to use long-term contraception - Informative and accessible health and care researchPharmacists gave the POP with emergency contraception - NIHR Evidence * * Evidence * About Us Sign UpWhat’s the issue?What’s new?Why is this important?What’s next?You may be interested to read Menu * Browse content * About Us * Glossary * Contact us * Site map * Cookies * Homepage * > * Giving the progestogen only pill along with emerge...Giving the progestogen only pill along with emergency contraception encouraged women to use long-term contraceptionHealth and Social Care Services
SMFM Statement: Response to EPPPIC and considerations of the use of progestogens for the prevention of preterm birth Society for Maternal-Fetal Medicine Statement: Response to EPPPIC and considerations for the use of progestogens for the prevention of preterm birth 3.30.21 An individual participant data (IPD) meta-analysis, “Evaluating Progestogens for Preventing Preterm birth International women at risk of preterm birth (PTB). Data from the Progestin’s Role in Optimizing Neonatal Gestation (PROLONG) trial were included in this meta-analysis. Outcomes included PTB (<37 weeks of gestation), early PTB (<34 weeks of gestation), and mid-trimester birth (<28 weeks of gestation). Adverse neonatal outcomes associated with PTB and adverse maternal outcomes were investigated as a composite
Clinical Guidance for the Integration of the Findings of the EPPPIC Meta-Analysis: Evaluating Progestogens for Preventing Preterm Birth International Collaborative Withdrawn Clinical Document | ACOG Skip to main content * Clinical Guidance * Practice Bulletin * Clinical Practice Guideline * Committee Statement * Committee Opinion * Clinical Consensus * Practice
Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN. Progestin-only injectable contraceptives, mainly depo-medroxyprogesterone acetate intramuscular (DMPA-IM), are the most widely used contraceptive methods in sub-Saharan Africa. Insufficient robust data on their relative side-effects and serum concentrations limit understanding of reported outcomes in contraception trials. The WHICH clinical trial randomized HIV-negative women to DMPA-IM (n = 262) or norethisterone enanthate (NET-EN) (n = 259) at two South African sites between 2018-2019. We measured serum concentrations of study and non-study progestins at initiation (D0) and peak serum levels, one week after
Correction: CDC2 Mediates Progestin Initiated Endometrial Stromal Cell Proliferation: A PR Signaling to Gene Expression Independently of Its Binding to Chromatin. [This corrects the article DOI: 10.1371/journal.pone.0097311.].
. This review highlights the effects of progestagens, including progesterone and synthetic progestins, on the brain, mood, stress, and cognition in females. The primary focus is on experimental pharmacological research that teases out the distinct effects of progestagens from those of estrogens. Additionally, the key literature on puberty, the menstrual cycle, pregnancy, perimenopause, hormonal contraceptives fronto-cingulate control over emotion processing. The interaction between progestagens and the systems involved in the regulation of stress seems to influence subjective experiences of mood and stress. Sparse studies investigating the effects of progestin-only contraceptives suggest effects of progestagens on the brain, mood, and stress. Progesterone and progestins used for contraception can influence
Use of progestogens and the risk of intracranial meningioma: national case-control study. To assess the risk of intracranial meningioma associated with the use of selected progestogens. National case-control study. French National Health Data System (ie, ). Of 108 366 women overall, 18 061 women living in France who had intracranial surgery for meningioma between 1 January 2009 and 31 December 2018 (restricted inclusion periods for intrauterine systems) were deemed to be in the case group. Each case was matched to five controls for year of birth and area of residence (90 305 controls). Selected progestogens were used: progesterone, hydroxyprogesterone, dydrogesterone, medrogestone, medroxyprogesterone acetate, promegestone, dienogest, and intrauterine levonorgestrel. For each progestogen
Long acting progestogens versus combined oral contraceptive pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open label, randomised controlled trial. To evaluate the clinical effectiveness of long acting progestogens compared with the combined oral contraceptive pill in preventing recurrence of endometriosis related pain. The PRE-EMPT (preventing recurrence of endometriosis) pragmatic, parallel group, open label, randomised controlled trial. 34 UK hospitals. 405 women of reproductive age undergoing conservative surgery for endometriosis. Participants were randomised in a 1:1 ratio using a secure internet facility to a long acting progestogen (depot medroxyprogesterone acetate or levonorgestrel releasing intrauterine system
Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls. Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD
Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial JCO We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg